Castleberry RP - Search Results

1

Hess JL, Zutter MM, Castleberry RP, Emanuel PD. Hess JL, et al. Among authors: castleberry rp. Am J Clin Pathol. 1996 Feb;105(2):238-48. doi: 10.1093/ajcp/105.2.238. Am J Clin Pathol. 1996. PMID: 8607451 Review.

2

A pilot study of isotretinoin in the treatment of juvenile chronic myelogenous leukemia.

Castleberry RP, Emanuel PD, Zuckerman KS, Cohn S, Strauss L, Byrd RL, Homans A, Chaffee S, Nitschke R, Gualtieri RJ. Castleberry RP, et al. N Engl J Med. 1994 Dec 22;331(25):1680-4. doi: 10.1056/NEJM199412223312503. N Engl J Med. 1994. PMID: 7605422 Free article. Clinical Trial.

3

PTEN deficiency is a common defect in juvenile myelomonocytic leukemia.

Liu YL, Castleberry RP, Emanuel PD. Liu YL, et al. Among authors: castleberry rp. Leuk Res. 2009 May;33(5):671-7. doi: 10.1016/j.leukres.2008.09.036. Epub 2008 Nov 17. Leuk Res. 2009. PMID: 19010541

4

Juvenile myelomonocytic leukemia: molecular understanding and prospects for therapy.

Emanuel PD, Shannon KM, Castleberry RP. Emanuel PD, et al. Among authors: castleberry rp. Mol Med Today. 1996 Nov;2(11):468-75. doi: 10.1016/1357-4310(96)10044-7. Mol Med Today. 1996. PMID: 8947912 Review.

5

Inhibition of juvenile myelomonocytic leukemia cell growth in vitro by farnesyltransferase inhibitors.

Emanuel PD, Snyder RC, Wiley T, Gopurala B, Castleberry RP. Emanuel PD, et al. Among authors: castleberry rp. Blood. 2000 Jan 15;95(2):639-45. Blood. 2000. PMID: 10627474 Free article.

6

Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors.

Emanuel PD, Bates LJ, Castleberry RP, Gualtieri RJ, Zuckerman KS. Emanuel PD, et al. Among authors: castleberry rp. Blood. 1991 Mar 1;77(5):925-9. Blood. 1991. PMID: 1704804 Free article.

7

The role of monocyte-derived hemopoietic growth factors in the regulation of myeloproliferation in juvenile chronic myelogenous leukemia.

Emanuel PD, Bates LJ, Zhu SW, Castleberry RP, Gualtieri RJ, Zuckerman KS. Emanuel PD, et al. Among authors: castleberry rp. Exp Hematol. 1991 Nov;19(10):1017-24. Exp Hematol. 1991. PMID: 1915702

8

Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1.

Side LE, Emanuel PD, Taylor B, Franklin J, Thompson P, Castleberry RP, Shannon KM. Side LE, et al. Among authors: castleberry rp. Blood. 1998 Jul 1;92(1):267-72. Blood. 1998. PMID: 9639526 Free article.

9

Development of an allele-specific minimal residual disease assay for patients with juvenile myelomonocytic leukemia.

Archambeault S, Flores NJ, Yoshimi A, Kratz CP, Reising M, Fischer A, Noellke P, Locatelli F, Sedlacek P, Flotho C, Zecca M, Emanuel PD, Castleberry RP, Niemeyer CM, Bader P, Loh ML. Archambeault S, et al. Among authors: castleberry rp. Blood. 2008 Feb 1;111(3):1124-7. doi: 10.1182/blood-2007-06-093302. Epub 2007 Nov 13. Blood. 2008. PMID: 18000165 Free PMC article.

10

Activating FLT3 mutations are rare in children with juvenile myelomonocytic leukemia.

Gratias EJ, Liu YL, Meleth S, Castleberry RP, Emanuel PD. Gratias EJ, et al. Among authors: castleberry rp. Pediatr Blood Cancer. 2005 Feb;44(2):142-6. doi: 10.1002/pbc.20176. Pediatr Blood Cancer. 2005. PMID: 15390271

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

108 results

Search Page

Filters